Xenetic Biosciences (XBIO) vs. Its Competitors Critical Review

Xenetic Biosciences (NASDAQ:XBIO – Get Free Report) is one of 843 publicly-traded companies in the “Biotechnology” industry, but how does it weigh in compared to its rivals? We will compare Xenetic Biosciences to similar businesses based on the strength of its valuation, dividends, risk, profitability, analyst recommendations, institutional ownership and earnings.

Earnings & Valuation

This table compares Xenetic Biosciences and its rivals top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Xenetic Biosciences $2.98 million -$2.68 million -0.96
Xenetic Biosciences Competitors $715.39 million $10.31 million -18.32

Xenetic Biosciences’ rivals have higher revenue and earnings than Xenetic Biosciences. Xenetic Biosciences is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Risk & Volatility

Xenetic Biosciences has a beta of 2.36, suggesting that its stock price is 136% more volatile than the S&P 500. Comparatively, Xenetic Biosciences’ rivals have a beta of -1.84, suggesting that their average stock price is 284% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and target prices for Xenetic Biosciences and its rivals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Xenetic Biosciences 1 0 0 0 1.00
Xenetic Biosciences Competitors 9931 15323 45708 1605 2.54

As a group, “Biotechnology” companies have a potential upside of 131.56%. Given Xenetic Biosciences’ rivals stronger consensus rating and higher possible upside, analysts clearly believe Xenetic Biosciences has less favorable growth aspects than its rivals.

Institutional & Insider Ownership

15.1% of Xenetic Biosciences shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 7.6% of Xenetic Biosciences shares are held by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Xenetic Biosciences and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Xenetic Biosciences -123.72% -53.79% -47.26%
Xenetic Biosciences Competitors -12,319.70% -407.93% -30.95%

Summary

Xenetic Biosciences rivals beat Xenetic Biosciences on 9 of the 12 factors compared.

Xenetic Biosciences Company Profile

(Get Free Report)

Xenetic Biosciences, Inc. is a biotechnology company focused on developing immuno-oncology treatments. Its XCART platform is designed to create personalized CAR T-cell therapies that recognize tumor-specific antigens on B-cell lymphomas, with the goal of targeting cancer cells while limiting effects on healthy cells. The company’s earlier work included PolyXen, a drug-delivery platform based on polysialic acid that was designed to extend the time biologic medicines remain in the body. Xenetic’s current stated focus is advancing its XCART technology and related product candidates.

Receive News & Ratings for Xenetic Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenetic Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.